NEW: DOJ Attorney Erin Colleran Deletes LinkedIn Account After Conflicts of Interest Exposed in Pfizer Fraud Case

Former FDA Chief Legal Counsel for Enforcement is now trying to dismiss Pfizer Clinical Trial Whistleblower Brook Jackson's Fraud Case that took place while she was employed by the FDA

Attorney, Erin Colleran, started her new role at the Department of Justice (DOJ) as a Trial Attorney in the Fraud section in 2021. Prior to Colleran’s role at the DOJ, from 2019 to 2021, Colleran was working at the Food & Drug Administration (FDA). 

Why is Colleran’s career history relevant? 

Well, that’s where things get interesting. Colleran is now representing the DOJ for alleged fraud crimes between Pfizer and the FDA that took place while she was the Chief Counsel of Regulatory Enforcement of the FDA. 

By transitioning from an attorney defending the interests of pharmaceutical companies to serving as the FDA’s Chief Counsel for Regulatory Enforcement to now being in charge of fraud cases at DOJ, Colleran exemplifies the intimate ties between the pharmaceutical industry and government agencies. Colleran’s story is just one of many that raises significant concerns regarding conflicts of interest and the risk of regulatory capture.

Colleran’s latest reaction to a post made by Attorney Robert Barnes, who’s representing Pfizer Whistleblower Brook Jackson in her lawsuit, was a tell-tale sign that she’s very much aware of her conflicts of interest. After Barnes posted on X calling out Colleran and her conflicts of interest, within minutes she deleted her LinkedIn profile. Which is an arguably an obvious reaction by someone who has something to hide. 

Colleran’s conflicts of interest are egregious. 

Any respectable, ethical attorney would have recused themselves from a case in which the they were the Chief Legal Counsel representing the organization directly involved in a fraud claim. 

However, instead of recusing herself, Colleran had the audacity to intervene in the case after 3 years of ongoing litigation—and after it appeared that the case would soon move to discovery—Colleran filed a request on behalf of the DOJ to dismiss the case.

The good news for Jackson & the 3 years of her life that she’s invested in this on-going litigation is that the case has not been dismissed. The DOJ now must prove to the court that they (the DOJ) are acting in good faith.

So why might Colleran want to dismiss this case?